Novan — Technical Presentation (June 2021)
16 slides from Novan's technical presentation, Jun 11, 2021
Slide 1: SB206: B-SIMPLE4 Top-Line Results
Nitric Oxide-Based Medicine novan.com NASDAQ: NOVN SB206: B-SIMPLE4 Top-Line Results June 11, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of our NITRICIL™ platform technology, our pharmaceutical development of nitric oxide-releasing product candidates, including SB206, th
Slide 3: Agenda
Agenda 3 • B-SIMPLE4: study design and demographics • Top-line efficacy: B-SIMPLE4 primary and secondary results • SB206 and molluscum indication: B-SIMPLE4 and B-SIMPLE2 • Molluscum market overview and commercial strategy
Slide 4: B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum
Treatment 12 Weeks Follow-up at Week 24 4 B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum Study Design Based on Learnings from B-SIMPLE1 and B-SIMPLE2: One and two-subject household stratification Inflammation of molluscum lesions added as a stratification factor1 Additional patient and caregive
Slide 5: Study Demographics and Disposition
Study Demographics and Disposition1 5 The B-SIMPLE4 pivotal trial was balanced across treatment arms and consistent with B-SIMPLE2 1. This table will be updated post completion of Week 24 data analysis and study closeout. 2. Intent-to-Treat Population (ITT): consists of all subjects who were randomi
Slide 6: B-SIMPLE4: ITT Population
B-SIMPLE4: ITT Population1 6 Positive study with robust clinical evidence of efficacy Primary Endpoint: Complete Clearance of All Lesions at Week 12 Secondary Endpoint: Proportion Achieving a Lesion Count of 0 or 1 at Week 12 SB206 (N=444) B-SIMPLE4 19.6% 11.6% Secondary Endpoint: Complete Clearance
Slide 7: Two Phase 3 Trials: Complete Clearance at Week 12
Two Phase 3 Trials: Complete Clearance at Week 121 7 Approximately a 31% increase in treatment difference from B-SIMPLE2 to B-SIMPLE4 1. Intent-to-Treat Population (ITT): consists of all subjects who were randomized. 20.3% 19.7% 30.0% 32.4% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% B-SIMPL
Slide 8: Summary of Adverse Events During 12-Week Treatment
Summary of Adverse Events During 12-Week Treatment1 8 B-SIMPLE4 B-SIMPLE2 SB206 (N=444) Vehicle (N=447) SB206 (N=237) Vehicle (N=117) Subjects with at least one Treatment Emergent Adverse Event (TEAE) 189 (42.6%) 103 (23.0%) 120 (50.6%) 29 (24.8%) Subjects with at least one Serious TEAE 0 1 (0.2%) 1
Slide 9: Summary of Treatment-Emergent Adverse Events
Summary of Treatment-Emergent Adverse Events 9 Note: through Week 12 visit, final safety profile will be updated through Week 24 and is targeted to be released in 3Q 2021. B-SIMPLE4 B-SIMPLE2 SB206 (N=444) Vehicle (N=447) SB206 (N=237) Vehicle (N=117) System Organ Class/Preferred Term Subjects[1] Su
Slide 10: SB206: Summary of B-SIMPLE Results
SB206: Summary of B-SIMPLE Results 10 B-SIMPLE4 was a positive Phase 3 study with robust clinical data SB206 demonstrates clinical evidence of efficacy B-SIMPLE2 will be included as the confirmatory trial per FDA guidance received in April 2020 We have confidence to move forward with NDA preparation
Slide 11: SB206: Next Steps
SB206: Next Steps 11 All safety data including the prospectively planned safety evaluation through Week 24, targeted to be available in 3Q 2021 Intend to utilize B-SIMPLE4 as the pivotal Phase 3 trial and B-SIMPLE2 as the confirmatory trial for New Drug Application ("NDA") submission1 Potential NDA
Slide 12: Molluscum: The Unmet Medical Need
Molluscum: The Unmet Medical Need 12 No FDA-Approved Treatments ~3.4 million prevalence in the U.S.1 ~1.3 million diagnosed per annum1 ~70% of patients below the age of 10 Average time to resolution 13 Months SB206: Potential to be the First FDA Approved Patient or Caregiver Administered Topical The
Slide 13: SB206 Commercialization Strategy
SB206 Commercialization Strategy 13 Evaluating All Strategic Options Goal: Maximize Value Novan Commercializes Secure Commercialization Partner Co-Commercialize with Partner
Slide 14: Thank You
THANK YOU!!! 14 Employees Patients Investigators Partners InvestorsCROs
Slide 15: Q&A
Q&A 15
Slide 16: Investor Relations Contact
Nitric Oxide-Based Medicine Investor Relations JTC Team 833.475.8247 novn@jtcir.com novan.com NASDAQ: NOVN